NKF(SH:603707)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥1,028,802,901.82, representing a year-on-year increase of 34.92%[4] - The net profit attributable to shareholders for Q3 2021 was ¥289,176,194.88, reflecting a growth of 41.30% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥286,514,905.94, an increase of 53.53% year-on-year[4] - The basic earnings per share for Q3 2021 was ¥0.10, up 42.86% from the previous year[5] - Total operating revenue for Q3 2021 reached ¥2,780,097,098.91, an increase from ¥2,158,370,025.18 in the same period last year, representing a growth of approximately 29%[30] - Total operating costs for Q3 2021 were ¥1,798,866,892.44, up from ¥1,477,005,628.88 year-over-year, indicating a rise of about 22%[30] - The net profit for Q3 2021 was approximately ¥845.42 million, an increase of 38.7% compared to ¥609.20 million in Q3 2020[31] - The total profit for Q3 2021 reached ¥975.44 million, up 39.9% from ¥697.56 million in the same period last year[31] - The basic earnings per share for Q3 2021 was ¥0.69, compared to ¥0.51 in Q3 2020, reflecting a growth of 35.3%[32] - The operating profit for Q3 2021 was approximately ¥964.37 million, an increase of 43.5% from ¥672.01 million in Q3 2020[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,362,409,903.85, an increase of 8.32% compared to the end of the previous year[5] - The total assets as of Q3 2021 were ¥8,362,409,903.85, up from ¥7,720,360,460.30 in the same quarter last year, marking a growth of about 8.3%[29] - Total liabilities decreased to ¥3,892,048,235.84 in Q3 2021 from ¥3,975,799,969.17 in the previous year, showing a reduction of approximately 2.1%[29] - The total equity attributable to shareholders increased to ¥4,448,005,600.38 in Q3 2021, compared to ¥3,722,438,519.79 in the same period last year, representing a growth of about 19.5%[29] Cash Flow - The company reported a net cash flow from operating activities of ¥245,829,942.23 for the year-to-date[5] - Cash flow from operating activities for the first three quarters of 2021 was ¥2.74 billion, an increase of 24.5% from ¥2.20 billion in the same period of 2020[33] - The net cash flow from investing activities in Q3 2021 was approximately ¥326.16 million, a significant improvement from a net outflow of ¥73.75 million in Q3 2020[36] - The company reported a net cash flow from financing activities of -¥346.18 million in Q3 2021, compared to a positive cash flow of ¥610.91 million in Q3 2020[36] - The company recorded a cash and cash equivalents balance of ¥717.22 million at the end of Q3 2021, up from ¥221.75 million at the end of Q3 2020[36] - The company reported a significant increase in cash and cash equivalents, reaching approximately CNY 738.34 million as of September 30, 2021, compared to CNY 493.55 million at the end of 2020, representing a growth of 49.7%[27] Research and Development - Research and development expenses for Q3 2021 amounted to ¥153,264,424.78, compared to ¥144,129,619.86 in the previous year, reflecting an increase of approximately 6%[30] - The company has established a comprehensive knowledge system for R&D and registration, enhancing its efficiency in product development and approval[17] - The company has established a standardized R&D and registration document management system, significantly improving the efficiency of product development and approval processes[23] Market Strategy and Expansion - The company plans to continue expanding its market presence and investing in new product development to sustain growth[9] - The company is expanding its product pipeline through both self-developed and externally sourced formulations to enhance market position and opportunities[20] - The company aims to leverage its compliance production capabilities to participate in global competition, focusing on the U.S. market as a breakthrough point[17] - The acquisition of the Meitheal team in the U.S. has strengthened the company's marketing channels and local market understanding, positioning it for growth in the sterile injection market[24] - The company is utilizing third-party clinical representatives to expand its sales channels and improve market penetration, effectively increasing sales scale in existing markets[25] Production and Quality Management - The new production line approved by the FDA increased the output of water injection formulations by over 300% and freeze-dried formulations by over 400%[16] - The company has five sterile formulation production lines approved by the FDA, positioning it as one of the few domestic companies with such certification[16] - The company has received approval for the production of new products at additional sites, with some products already granted approval by the FDA, enhancing production capabilities[22] - The company has implemented lean management practices to improve operational efficiency across production, quality, R&D, registration, marketing, and sales, aiming for zero defects in product quality[23] - The company aims to maintain high product standards by adhering to FDA regulations and continuously improving internal quality standards, ensuring competitiveness in global markets[23] Financial Investments - The company reported a net investment income of ¥13,999,306.87 for Q3 2021, significantly higher than ¥3,426,754.95 in the same quarter of the previous year[30] - The company’s long-term equity investments rose to ¥6,458,479.72 in Q3 2021, compared to ¥3,258,879.55 in the same period last year, reflecting an increase of about 98%[28] - The company’s goodwill stood at ¥118,246,373.89 in Q3 2021, slightly up from ¥117,556,457.24 in the previous year, indicating a marginal increase of about 0.6%[28]